Perhaps even more deserving of consideration would be whether Myc inhibitors should be used in children in whom even relatively short courses of standard cancer chemotherapy can elicit features of premature aging and might collaborate with agents that deliberately lowered Myc levels (Smitherman et al., 2020; Kruseova et al., 2023). Here, MYC is linked to cancer.